glp 1 weight loss covered by insurance Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for Insurance coverage just changed for

GLP-1 medicines available in India in 2026 Two molecules dominate: semaglutide (a GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist)

Kovalzon VM

Results at 68 weeks: 40.4% of CagriSema participants lost 25% or more of their body weight 91.9% lost at least 5% Blood pressure fell by 10.9 mmHg systolic on average About 40% of participants reduced or stopped blood pressure medications 87.7% of those with prediabetes at baseline achieved normal blood sugar Results were published in the New England Journal of Medicine and presented at the American Diabetes Associations 2026 Scientific Sessions

Cellular Therapy and Stem Cells can actively modulate inflammatory processes in the central nervous system, repair damaged neurocircuitry, enhance melatonin production, balance neurotransmitters, and reset circadian rhythms at the cellular level